Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial

Jemal, 2006, Cancer statistics, 2006, CA Cancer J Clin, 56, 106, 10.3322/canjclin.56.2.106

Vasudevan, 2006, Incidental renal tumours: the frequency of benign lesions and the role of preoperative core biopsy, BJU Int, 97, 946, 10.1111/j.1464-410X.2006.06126.x

Linehan, 2003, The genetic basis of cancer of the kidney, J Urol, 170, 2163, 10.1097/01.ju.0000096060.92397.ed

Kattan, 2001, A postoperative prognostic nomogram for renal cell, J Urol, 166, 63, 10.1016/S0022-5347(05)66077-6

Sorbellini, 2005, A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma, J Urol, 173, 48, 10.1097/01.ju.0000148261.19532.2c

Motzer, 2002, Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology, J Clin Oncol, 20, 2376, 10.1200/JCO.2002.11.123

Lee, 2000, Surgical management of renal tumors of 4 cm or less in a contemporary cohort, J Urol, 163, 730, 10.1016/S0022-5347(05)67793-2

Dash, 2006, Comparison of outcomes in elective partial versus radical nephrectomy for clear cell renal cell carcinoma 4-7cm in size, BJU Int, 97, 939, 10.1111/j.1464-410X.2006.06060.x

Oosterwijk, 2003, Monoclonal antibody-based therapy for renal cell carcinoma, Urol Clin North Am, 30, 623, 10.1016/S0094-0143(03)00028-4

Uemura, 1999, MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas, Br J Cancer, 81, 741, 10.1038/sj.bjc.6690757

Bui, 2003, Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy, Clin Cancer Res, 9, 802

Bui, 2004, Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma, J Urol, 171, 2461, 10.1097/01.ju.0000116444.08690.e2

Steffens, 1997, Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250, J Clin Oncol, 15, 1529, 10.1200/JCO.1997.15.4.1529

Bleumer, 2006, A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma, J Urol, 175, 57, 10.1016/S0022-5347(05)00040-6

Brouwers, 2005, Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response, Clin Cancer Res, 11, 7178s, 10.1158/1078-0432.CCR-1004-0010

Divgi, 2004, Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer, J Nucl Med, 45, 1412

Bleumer, 2004, A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients, Br J Cancer, 90, 985, 10.1038/sj.bjc.6601617

Steffens, 1999, Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250, Clin Cancer Res, 5, 3268s

Divgi, 1998, Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma, Clin Cancer Res, 4, 2729

Juweid, 2006, Positron-emission tomography and assessment of cancer therapy, N Engl J Med, 354, 496, 10.1056/NEJMra050276

Larson, 1992, PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma, J Nucl Med, 33, 2020

Larson SM, Finn R, Carrasquillo JA, et al. Antigen-specific composition and in vivo methods for detecting and localizing an antigenic site and for radiotherapy. US patent No. 5,185,142. Date: Feb 9, 1993.

Verel, 2003, Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET, Cancer Biother Radiopharm, 18, 655, 10.1089/108497803322287745

Welt, 1990, Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33, J Clin Oncol, 8, 1894, 10.1200/JCO.1990.8.11.1894

Brouwers, 2002, 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study, Nucl Med Commun, 23, 229, 10.1097/00006231-200203000-00005

Richstone, 2004, Multifocal renal cortical tumors: frequency, associated clinicopathological features, and impact on survival, J Urol, 171, 615, 10.1097/01.ju.0000106955.19813.f6

Stevens, 2006, Assessing kidney function—measured and estimated glomerular filtration rate, N Engl J Med, 354, 2473, 10.1056/NEJMra054415

Huang, 2006, Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study, Lancet Oncol, 7, 735, 10.1016/S1470-2045(06)70803-8